重庆智飞生物:卓越的疫苗和生物制品研发公司-基础柱状图-数据可视化

智飞生物(300122),全称重庆智飞生物制品股份有限公司(Chongqing Zhifei Biological Products Co., Ltd.),主营业务为疫苗、生物制品的研发、生产和销售。,位于重庆重庆市,董事长为蒋仁生,总经理为蒋仁生。网址为www.zhifeishengwu.com。

《重庆智飞生物:卓越的疫苗和生物制品研发公司》重庆智飞生物拥有非常卓越的研发能力,在业界被广泛认可。该公司的主营业务是研发、生产和销售疫苗和生物制品。公司的董事长和总经理蒋仁生,这也说明了该公司的专注、团结精神和抗压性,与其他专业公司有较大区别。从收入报表可以看出,公司的财务状况一直保持良好,自2013年至2022年,所有者权益(或股东权益)合计的累计增长情况也非常棒。这也说明该公司经营管理水平的提高及其产品和技术的发展。重庆智飞生物将继续努力,将品牌声誉提升至更高水平,继续在疫苗和生物制品研发领域获得更多的成就。

重庆智飞生物是一家专注于研发、生产和销售疫苗和生物制品的生物制药公司,致力于提供优质的产品和服务。,"300122","智飞生物","Zhifei Biological","蒋仁生","蒋仁生","ESG 300","创业板50","创业板指","创业新兴","分析师指数","国证A50","国证A指","沪深300","巨潮100","巨潮大盘","深成指R","深证100","深证100R","深证300","深证成指","深证新兴","深证责任","中创100","中证100","中证新兴","数据可视化","上市公司财报","数据分析","基础柱状图","花火数图","图表"

我也要免费做基础柱状图

重庆智飞生物是一家专注于研发、生产和销售疫苗和生物制品的生物制药公司,致力于提供优质的产品和服务。,"300122","智飞生物","Zhifei Biological","蒋仁生","蒋仁生","ESG 300","创业板50","创业板指","创业新兴","分析师指数","国证A50","国证A指","沪深300","巨潮100","巨潮大盘","深成指R","深证100","深证100R","深证300","深证成指","深证新兴","深证责任","中创100","中证100","中证新兴","数据可视化","上市公司财报","数据分析","基础柱状图","花火数图","图表"

我也要免费做基础柱状图

报表日期所有者权益(或股东权益)合计
2022123124,236,212,609.17
2021123117,657,212,911.83
202012318,248,664,459.27
201912315,747,337,629.12
201812314,180,898,895.83
201712312,937,532,367.69
201612312,521,256,967.01
201512312,469,228,813.85
201412312,457,738,732.54
201312312,389,259,841.00
201212312,376,008,932.37
201112312,258,065,072.91
201012312,141,681,447.39
20091231451,690,420.69
20081231267,058,318.39
20071231188,032,059.05

我也要免费做基础柱状图